Protara Therapeutics (TARA) Short term Debt (2013 - 2020)

Protara Therapeutics (TARA) recorded quarterly Short term Debt of $370793.0 in Q3 2020, down 60.0% quarter-over-quarter from $926983.0 in Q2 2020.

Protara Therapeutics (TARA) Short term Debt (2013 - 2020) Analysis & Trends

Protara Therapeutics' Short term Debt history runs 2 years deep, the most recent figure standing at $370793.0 for Q3 2020.

In Q3 2020, Short term Debt changed N/A year-over-year to $370793.0; the TTM figure through Sep 2020 stood at $370793.0 (changed N/A YoY), while the FY2013 annual figure was $1.4 million, changed N/A from the prior year.
Short term Debt was $370793.0 for Q3 2020 at Protara Therapeutics, down from $926983.0 in the prior quarter.
In the past five years, Short term Debt ranged from a high of $1.3 million in Q1 2020 to a low of $370793.0 in Q3 2020.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	762,369.55 Bn	762,369.51 Bn	-
2	Belite Bio	55,096.00 Bn	55,096.00 Bn	-
3	Quantum Biopharma	17,755.80 Bn	17,755.79 Bn	-
4	Legend Biotech	3,486.00 Bn	3,485.71 Bn	242.10 Mn
5	Akari Therapeutics	1,737.42 Bn	1,737.41 Bn	-
6	Evaxion A	1,551.28 Bn	1,551.26 Bn	-
7	Psyence Biomedical	227.32 Bn	227.31 Bn	-
8	Vertex Pharmaceuticals	110.84 Bn	103.59 Bn	2.59 Bn
9	Abivax	91.71 Bn	91.71 Bn	-
10	Protara Therapeutics	216.35 Mn	216.35 Mn	-

Download Data